Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
10,018 total articles
GigaCloud Technology Inc. (NASDAQ: GCT) reported insider sales totaling 125,150 Class A Ordinary Shares executed by CEO Lei Wu and two entities he controls between March 3 and March 5, 2026. The disposals, conducted under a pre-arranged 10b5-1 trading plan, generated roughly $5.4 million at prices spanning $40.44 to $44.94 per share. The filings no…
Cathy A. King, Chief Legal Officer and Corporate Secretary of PAR Technology Corp (NYSE: PAR), completed non-discretionary sales of 7,626 shares on March 3 and 4, 2026, to satisfy tax-withholding obligations tied to restricted stock unit vesting. The transactions, disclosed on a Form 4 filing with the SEC, totaled approximately $134,562 and occurre…
CoreWeave Chief Financial Officer Nitin Agrawal sold 4,920 shares of Class A common stock on March 3, 2026, for proceeds of $286,935 under a previously adopted Rule 10b5-1 plan. The transaction comes amid robust company revenue growth, a new AI partnership, and contrasting analyst opinions on valuation and outlook.
NextNav Inc. CEO, President and Director Mariam Sorond sold 69,853 shares on March 3, 2026 under a Rule 10b5-1 plan, realizing roughly $1.18 million to meet tax-withholding obligations tied to equity vesting. The transactions leave Sorond with 1,270,946 shares. Separately, NextNav appointed Lisa Hook as lead independent director and expanded its pa…
Savi Luca, President and CEO of ITT Inc., sold 65,513 shares of company common stock on March 5, 2026, for roughly $12 million in a series of trades at prices between $188.981 and $193.7113 per share. The Form 4 filing states the sale was to facilitate the purchase of a new personal residence near ITT's headquarters. These transactions follow the s…
Michael Anthony Steenberge, Chief Accounting Officer at PAR Technology (NYSE:PAR), sold 2,924 shares on March 3 and 4, 2026 for roughly $51,594 to cover tax obligations tied to vested restricted stock units. The sales were completed under a mandatory sell-to-cover rule in a Rule 10b5-1 plan adopted June 3, 2025, and were not discretionary trades. T…
Par Technology CORP Chief Financial Officer Bryan A. Menar sold 8,224 shares of common stock on March 3 and 4, 2026, in two transactions that generated $145,113 in proceeds. The sales were automatic sell-to-cover transactions tied to restricted stock unit vesting and were carried out under a Rule 10b5-1 plan. The stock trades below its 52-week peak…
Par Technology CEO Singh Savneet sold 71,915 shares across two transactions on March 3 and 4, 2026, raising roughly $1.26 million. The sales were disclosed on a Form 4 and were made under a mandatory sell-to-cover arrangement tied to the vesting of restricted stock and performance-based restricted stock units. The company faces valuation scrutiny a…
Delek US Holdings President and CEO Avigal Soreq sold 50,000 shares on March 3, 2026, generating roughly $2.05 million in proceeds through three transactions executed under a 10b5-1 plan. The stock has climbed sharply over the past year and is trading near its 52-week high, while independent analysis flags the shares as overvalued versus Fair Value…
Kevin Maddock, Executive Vice President at Rimini Street (NASDAQ: RMNI), sold 2,809 shares on March 3, 2026, for a total of $10,445 to satisfy tax obligations tied to vesting restricted stock units. The company reported profitability over the trailing twelve months and trades at a P/E ratio of 9.53. Separately, Tidewater Inc. has broadened its use …
Corvex Management LP and director Keith A. Meister disclosed purchases of GeneDx Holdings Corp. (NASDAQ: WGS) Class A Common Stock totaling about $13.4 million. The transactions took place on March 3 and March 5, 2026, at prices between $70.34 and $82.06. The buying activity arrives after a 38% decline in the stock over the past six months and amid…
Adaptive Biotechnologies Corp executive Julie Rubinstein sold 92,823 shares of common stock for roughly $1.49 million between March 3 and March 5, 2026, and exercised options to acquire 73,610 shares at $6.55 and $12.14. The stock is trading at $15.93, up 105% over the past year; InvestingPro analysis notes possible overvaluation versus its Fair Va…
Halide Alagoz, Chief Product & Merchandising Officer at Ralph Lauren Corp (NYSE:RL), sold 1,120 shares of Class A Common Stock on March 4, 2026, for $362.00 per share, totaling $405,440, according to a Form 4 filed with the SEC. After the transaction Alagoz holds 21,113 shares directly. The filing notes the sale was part of a long-term plan for est…
John W. Schlosser, Vice President and President, Terminals at Kinder Morgan, sold 6,166 shares of Class P common stock on March 5, 2026, for about $207,640 under a 10b5-1 trading plan. The stock has risen roughly 28% over six months and is trading close to its 52-week high. Multiple analysts reconfirmed or raised targets after Kinder Morgan's stron…
Rimini Street Executive Vice President and Chief Marketing Officer David W. Rowe exercised 6,667 options with a zero exercise price and sold 2,809 shares on March 3, 2026, in a transaction automatically triggered to meet tax-withholding obligations. After the transactions Rowe directly holds 457,789 shares. Rimini Street shares trade below Investin…
LeonaBio President and CEO Mark James Litton reported a sale of 5,156 shares on March 4, 2026, raising $27,687 at a weighted-average price of $5.37 per share after exercising options the prior day. The transaction comes amid corporate restructuring, a major licensing deal for lasofoxifene and fresh financing and analyst coverage that have shaped ma…
Beta Bionics NASDAQ:BBNX Chief Commercial Officer Hopman Mark sold 353 shares on March 4, 2026, at $11.57 per share for about $4,084. The transaction was executed under a Rule 10b5-1 plan adopted May 13, 2025, and was disclosed in a Form 4 filing. The stock has fallen 12% over the past week and is down 64% year-to-date. Analysts continue to offer d…
Timothy R. Barakett, a director at KKR & Co. Inc., purchased 50,000 shares of common stock on March 4, 2026, for roughly $4.72 million. The trade comes amid a quarter in which KKR missed consensus adjusted EPS and as the firm pursues potential disposals and strategic partnerships, including a possible sale of BMC Helix and talks about a renewable-e…
Stephen L. Rohde, a director at Slide Insurance Holdings, Inc. (NYSE: SLDE), sold 10,000 shares across March 3 and March 4, 2026, for about $193,300 and simultaneously exercised options to buy 10,000 shares for $0.0018 each. The transactions occurred as SLDE stock has risen 42% over six months and after the company reported a sizable fourth-quarter…
Voss Capital and affiliated vehicles purchased $14.6 million of PAR Technology (NASDAQ: PAR) shares between January 14 and February 4, 2026, paying between $22.1999 and $39.1047 per share. The trades increased Voss-linked direct holdings and included several call option purchases. The activity comes as PAR shares trade at $19.52, down 68% over the …
Matthew Paul Larson, Chief Risk Officer of Slide Insurance Holdings Inc. (NASDAQ:SLDE), sold 11,250 shares on March 3, 2026, for roughly $213,862 and concurrently exercised options on 11,250 shares at $0.79 per share. The moves were disclosed in a Form 4 filing and occur amid solid quarterly results and valuation metrics showing SLDE trading at a P…
Castle Biosciences Inc (NASDAQ:CSTL) Chief Financial Officer Frank Stokes sold 7,000 shares on March 3, 2026, in two tranches that generated roughly $192,073. Around the same time he sold additional shares to cover taxes and exercised options to acquire nearly 28,000 shares while receiving 48,367 restricted stock units. The activity coincides with …
LeonaBio, Inc. (NASDAQ: LONA) reported a modest insider sale by Chief Financial Officer Robert Renninger tied to taxes on vested restricted stock units, alongside disclosures that include option exercises and a remaining direct holding of 15,851 shares. The company is navigating a strategic pivot toward oncology with licensed global rights for laso…
Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc. (BCAX), sold 17,392 shares on March 3, 2026, for about $315,892 and concurrently exercised options to acquire 12,892 shares. The transactions were carried out under a Rule 10b5-1 plan adopted February 12, 2025. Bicara has recently completed a large stock offering and received an analyst r…
Intuitive Surgical's SVP and head of manufacturing and supply chain, Brosius Mark, sold 3,658 shares of company stock in three transactions between March 3 and March 5, 2026, for a total of $1,815,061. The disposals were carried out under a Rule 10b5-1 trading plan set to expire February 14, 2027. Separately, the company reported robust fourth-quar…
